NextCure Inc (FRA:2US)

€ 0.783 -0.138 (-14.98%) Market Cap: 22.04 Mil Enterprise Value: -45.05 Mil PE Ratio: 0 PB Ratio: 0.30 GF Score: 28/100

NextCure Inc at JMP Securities Life Sciences Conference Transcript
May 16, 2023
NextCure Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 19, 2023
NextCure Inc at Bank of America Biotech SMID Cap Conference Transcript
Dec 08, 2022
NextCure Inc at Bank of America Healthcare Conference Transcript
May 10, 2022
NextCure Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
NextCure Inc Investor & Analyst Oncology Pipeline Update Event Transcript
Nov 15, 2021
NextCure Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
NextCure Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 12, 2021
NextCure Inc Virtual R&D Update Transcript
Mar 04, 2021
NextCure Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2020
NextCure Inc Annual Shareholders Meeting Transcript
Jun 11, 2020
NextCure Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 13, 2020
NextCure Inc at Needham Healthcare Conference Transcript
Apr 15, 2020
NextCure Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
NextCure Inc Updated Clinical Data from NC318 Phase 1/2 Clinical Trial Presentation Transcript
Nov 09, 2019

NextCure Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 19, 2023 / 02:15PM GMT

Release Date Price: €1.43 (+3.62%)

Transcript

Gil Blum

Needham & Company - Analyst

Hello, everyone, and thank you for joining me this morning at the third day of the Needham and Company Healthcare Conference. This morning, I have with me Michael Richman, the President and CEO of NextCure. Michael, with that, you have the stage.

Michael Richman

NextCure, Inc. - President & CEO

Great. Thank you so much, Gil, and thanks to the Needham team for including NextCure in the Annual Virtual Healthcare Conference this year. It's great to be with everyone and look forward to walking you through an update on NextCure and our approach towards treating cancer by restoring immune function.

This is our forward-looking statement on slide 2, and now moving into slide 3. This outlines the NextCure opportunity, which we think is quite unique even during these changing times. Our pipeline that I'll walk you through today is quite differentiated. We have three ongoing clinical programs based on novel targets and diverse indications. Each of those three programs will have readouts and updates in this year in

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.